First ADVANCE trial site to begin enrollment in the Netherlands
CYTX received approval from The Netherlands to initiate a pivotal European trial, named ADVANCE, to investigate adipose-derived stem and regenerative cells (ADRCs) processed by the Celution® One System, in the treatment of patients with acute heart attacks.
- This is the 1st country and trial center approval for ADVANCE;
- Additional country and trial center approvals are anticipated throughout Europe during the first half of 2011;
- One of the goals of the trial is to expand the Celution® System CE Mark to include acute heart attack claims and to provide economic data to justify its implementation and reimbursement.
ADVANCE is a randomized, placebo controlled, double-blind trial that will enroll up to 360 patients with ST-elevation myocardial infarction in up to 35 centers, predominately in Europe.
- The primary endpoint of the trial is reduction in infarct size as measured by cardiac magnetic resonance imaging (MRI);
- ADVANCE will use the Celution® One, its next generation device manufactured by Olympus-Cytori Joint Venture;
- The Celution® One System is an investigational device that is not yet commercially available.
In 2010, Cytori reported results from the APOLLO trial, a pilot study for acute heart attack patients who underwent ADRC therapy.
- The study showed that the harvest and injection of ADRCs were safe and well-tolerated in this patient population;
- At 6 months, the procedure was associated with an improvement in infarct size in ADRC-treated patients, as well as in other measures.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.